Spectral AI Details 2026 Commercial Launch Plan Following FDA DeepView System Clearance

Spectral AI (MDAI) announced its strategic outlook and commercialization plan after receiving FDA De Novo Classification for its DeepView® System for burn indications. The company is now authorized to begin commercial distribution in the United States and anticipates its first-ever commercial sales by the end of 2026.

Key Details

• FDA Clearance: Received De Novo Classification from the U.S. Food and Drug Administration (FDA) for its DeepView® System, which authorizes the start of commercial distribution activities in the United States.
• Commercial Launch Plan: Aims to generate first commercial sales by year-end 2026. The initial U.S. rollout includes a BARDA-funded procurement of up to 30 DeepView devices. International sales in the UK, Australia, or GCC nations are targeted for Q4 2026.
• Shareholder Approvals: At the Annual Meeting on May 29, 2026, stockholders approved all company proposals, including the election of five directors and the authorization to issue common stock to Hudson Bay Master Fund Ltd. pursuant to a prior agreement.